A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection

This study has been completed.

Sponsor:

Information provided by:

MedImmune LLC

ClinicalTrials.gov Identifier:

NCT00192504

First received: September 13, 2005

Last updated: October 23, 2006

Last verified: October 2006

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	January 2005
Estimated Primary Completion Date:	No date given